Tag Archives: Heron Therapeutics

June, 2018

21 June
FDA Grants Breakthrough Therapy Designation to Heron’s HTX-001 for Postoperative Pain Management

SAN DIEGO–(BUSINESS WIRE)–Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that HTX-011 for postoperative pain management has received Breakthrough Therapy designation from the U.S. Food and …
Share

10 August
FDA Approves Heron’s Sustol Extended-Release Injection for the Prevention of CINV

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Heron Therapeutics, Inc. (NASDAQ:HRTX), today announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection. SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with …
Share

29 May
Heron’s Investigational CINV Drug Succeeds in Late-Stage Study

Heron Therapeutics said that its experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) met its primary endpoint in a late-stage study. Following repeated delays, the positive news sent the company’s shares up more than 40 percent in extended trading. Heron announced top-line results from its Phase III MAGIC study, …
Share